Based on positive data from the Phase 1b EQUATE study, EQUATOR is a global Phase 3 clinical study comparing the efficacy and safety of itolizumab versus placebo as a first-line therapy for patients with Grade III-IV acute graft-versus-host disease (aGVHD) or Grade II aGVHD patients with LGI involvement, in combination with corticosteroids.

A Phase 1b, multiple-ascending-dose study of itolizumab (EQ001) in subjects with systemic lupus erythematosus with or without active proliferative lupus nephritis